S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
Stock market today: World shares shrug off Wall St blues as investors eye corporate earnings
Japan's anti-monopoly body orders Google to fix ad search limits affecting Yahoo
NASDAQ:BNOX

Bionomics (BNOX) Stock Price, News & Analysis

$0.98
0.00 (-0.06%)
(As of 04/19/2024 08:50 PM ET)
Today's Range
$0.96
$0.99
50-Day Range
$0.93
$1.30
52-Week Range
$0.87
$6.41
Volume
14,400 shs
Average Volume
200,659 shs
Market Capitalization
$7.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Bionomics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
818.9% Upside
$9.00 Price Target
Short Interest
Healthy
3.17% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.59) to ($4.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.19 out of 5 stars

BNOX stock logo

About Bionomics Stock (NASDAQ:BNOX)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. The company has a collaboration with Merck & Co., Inc. to identify novel a7 Nicotinic Acetylcholine Receptor PAMs suitable for the treatment of cognitive disorder. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNOX Stock Price History

BNOX Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
Bionomics Provides a Review of 2023 and of 2024 Plans
Bionomics Ltd ADR BNOX
Bionomics Limited (BNOX)
Why Is Bionomics (BNOX) Stock Up 347% Today?
Bionomics Ltd: Quarterly Activities and Cashflow Report
See More Headlines
Receive BNOX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/22/2024
Next Earnings (Estimated)
4/22/2024
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:BNOX
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$10.00
Low Stock Price Target
$8.00
Potential Upside/Downside
+818.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$2.73 per share

Miscellaneous

Free Float
8,038,000
Market Cap
$7.99 million
Optionable
Not Optionable
Beta
-0.09
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Spyridon Papapetropoulos M.D. (Age 51)
    Ph.D., CEO, President & Director
    Comp: $498.92k
  • Mr. Adrian Hinton BEC (Age 71)
    F.C.A., Financial Controller
    Comp: $193.97k
  • Mr. Timothy M. Cunningham CPA (Age 61)
    M.B.A., Chief Financial Officer
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Dr. Julie Kerner Ph.D.
    Senior Vice President of Business Operations
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Secretary

BNOX Stock Analysis - Frequently Asked Questions

Should I buy or sell Bionomics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bionomics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BNOX shares.
View BNOX analyst ratings
or view top-rated stocks.

What is Bionomics' stock price target for 2024?

2 Wall Street analysts have issued twelve-month target prices for Bionomics' stock. Their BNOX share price targets range from $8.00 to $10.00. On average, they expect the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 818.9% from the stock's current price.
View analysts price targets for BNOX
or view top-rated stocks among Wall Street analysts.

How have BNOX shares performed in 2024?

Bionomics' stock was trading at $1.48 at the start of the year. Since then, BNOX stock has decreased by 33.8% and is now trading at $0.9794.
View the best growth stocks for 2024 here
.

Are investors shorting Bionomics?

Bionomics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 258,400 shares, an increase of 344.0% from the March 15th total of 58,200 shares. Based on an average daily volume of 213,800 shares, the days-to-cover ratio is presently 1.2 days.
View Bionomics' Short Interest
.

When is Bionomics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 22nd 2024.
View our BNOX earnings forecast
.

When did Bionomics IPO?

Bionomics (BNOX) raised $20 million in an initial public offering on Thursday, December 16th 2021. The company issued 1,622,000 shares at a price of $12.35 per share.

How do I buy shares of Bionomics?

Shares of BNOX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BNOX) was last updated on 4/22/2024 by MarketBeat.com Staff

From Our Partners